Prevalence Of Hepatitis C Virus Antibadies İn Different Patient Groups

The hepatitis C Virus (HCV) is now known to be the chief cause of transfusion-associated non-A non-B hepatitis (NANBH). The prevalence of HCV infection was as-sessed by means of Abbott enzyme-linked immunosorbent assay for serum anti-HCV antibodies. 2222 serum samples were selected from different patient groups, accor¬ding to their risk of blood-borne viral infections. Anti-HCV antibodies were detected in 25 of 83 (30.12%) risk group (Haemodialysis patients and polytransfused patients with haemophilia, thalassemia, patients of cardiac surgery). Among healtyh subjects, wit¬hout risk factors for hepatitis, the overall prevalance of Anti-HCV was (0.14%). Hepatit C virusu (HCV), transfuzyon ile iliskili non-A, non-B hepatiti (NANBH)'nin baslica nedenidir. HCV infeksiyon prevalansi Abbott'un anti-HCV antikorlari icin enzy-me-linked immunosorbent assay (ELISA) test kiti kullanilarak saptanmistir. 2222 serum ornegi, kan yoluyla viral infeksiyon bulasma riski olan degisik hasta gruplarindan toplanmistir. Anti-HCV antikorlari 83 risk grubunun (hemodiyaliz hastasi, he¬mofili, thalassemi gibi politransfuze hastalar ve kalp cerrahisi hastalari) 25 (%30.12)'inde saptanmistir. Hepatit risk faktoru bulunmayan saglikli bireylerde anti-HCV prevalansi ise %0.14 olarak saptanmistir.